Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer – OncLive
OncLive |
Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer
OncLive John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer. Most of the trials have been conducted with single-agent checkpoint inhibitors, explains Wagstaff. |
